Skip to content

Trial · Interventional

TerminatedNot applicableRegistry data

Influence of Aromatase Inhibitors and GnRH Analogs to Treat Uterine Leiomyoma by Vaginal Hysterectomy

NCTNCT01280045 (opens ClinicalTrials.gov in a new tab)Other idFMRPUSP-UROGIN-001
Open at ClinicalTrials.govAsk about this trial

This trial does not test a peptide that PepBank tracks.

  • Names Goserelin, does not test it. It appears in the title.

Overview

Status
Terminated
Phase
Not applicable
Enrollment
5 participants (actual)
Sponsor
University of Sao Paulo · Other
Design
Randomized · Double masking
Countries
Not stated
Start
Jan 2011
Primary completion
May 2013
Completion
Jan 2015
First posted
20 Jan 2011 (estimated)
Last update posted
13 Aug 2020
Conditions
UTERINE LEIOMYOMA

Timeline

1 trial · 1 stopped early

  • Completed
  • Ongoing
  • Not yet recruiting
  • Stopped
  • Estimated dates (est.)
  • Results posted
201120122013201420152016
  1. N/A

    Influence of Aromatase Inhibitors and GnRH Analogs to Treat Uterine Leiomyoma by Vaginal Hysterectomy

    NCT01280045

    Jan 2011 to Jan 2015

    Terminated

Registry summary

Text and fields below are the sponsor's entries at ClinicalTrials.gov, shown as posted.

The investigators aimed to assess if use of aromatase inhibitors could decrease volume of uterine leiomyoma and cause same percentage of adverse effects during its use compared to GnRH analogs.

Interventions

  • VAGINAL HYSTERECTOMYProcedure

Arms2

  • Experimental

    AROMATASE INHIBITOR

    this would be compared before and after VAGINAL HYSTERECTOMY

  • Active comparator

    GNRH ANALOG

    this would be compared before and after VAGINAL HYSTERECTOMY

Primary outcomes1

Outcomes the sponsor listed as primary.

  1. Operative Time

    Time frame · Intra-operative

    Registry description

    Intra-operative time

Secondary outcomes(1)

  1. Uterine Leiomyoma Volume

    Time frame · 3 Months After Treatment, During Surgery

    Registry description

    Volume measured by ultrasound

Posted results

Values are shown as posted at ClinicalTrials.gov, with their units. PepBank has not converted, pooled or compared them.

No results are posted for this trial.

A trial that is still running, or that stopped early, may post results later.

Registry data comes from ClinicalTrials.gov. Study results come from studies, not from the registry. How PepBank works

Studies1

Studies that cite this trial.

Studies with results

1 study on this page

Indexing hint: Randomized controlled trial · 2010

2 results

A randomized, controlled clinical trial comparing the effects of aromatase inhibitor (letrozole) and gonadotropin-releasing hormone agonist (triptorelin) on uterine leiomyoma volume and hormonal status.

Parsanezhad et al. 2010Fertility and sterilitycited by 90

PMID 19135657DOI 10.1016/j.fertnstert.2008.09.064PUB-19135657

Rights unknown2 results
Source linkSee results (2)

Eligibility

Who could join, as posted.

Sex
Female
Age
from 40 Years up to 60 Years
Healthy volunteers
Accepted
Inclusion and exclusion criteria, as posted
Inclusion Criteria: * WOMEN OVER 40 YEARS, UTERINE VOLUME HIGHER THAN 300 ML, MINIMAL ANATOMIC CONDITIONS FOR VAGINAL SURGERY Exclusion Criteria: * ACTIVE GYNECOLOGIC MALIGNANCY

PepBank is a research reference. Talk to a doctor before you use any peptide.